Acceleron drug for rare blood disorder slated for late-stage trials next year
November 21, 2014 at 12:35 PM EST
Acceleron Pharma's most advanced drug in development may be aiming at the same disease as its Cambridge neighbor, bluebird bio, but CEO John Knopf says there's room in the market for the two very different approaches to the same rare disease...
